Developing an AI-guided triculture platform to model neurohiv specific microglial states under art suppression with cellpaint/morphological and transcriptomic readouts
Active Grant Awarded
- Award ID
- R61MH143793
- Recipient
-
Modulo Bio, Inc. UEI U1TNJGPGNHA9
- Awarding agency
-
National Institute of Mental Health
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,479,470
Award facts
- Assistance listing
- 93.242 Mental Health Research Grants
- Completion date 36% complete
- Place of performance
- California, USA
Award details come from USAspending.gov.
About this award
The National Institutes of Health's National Institute of Mental Health, within the Department of Health and Human Services, awarded Modulo Bio, Inc. a grant obligating $1.47947 million on February 25, 2026, under the Mental Health Research Grants program (CFDA 93.242). Grant R61MH143793 funds development of an AI-guided triculture platform combining induced pluripotent stem cell (iPSC)-derived microglia, astrocytes, and neurons to model HIV-associated brain injury under antiretroviral therapy (ART) suppression. The work applies AI/machine learning morphological profiling and multi-omic data integration to classify microglial functional states and their impact on neuronal health. The stated objectives are to develop and validate an HIV-infected, ART-suppressed triculture platform, and to characterize it through neuroinflammatory profiling, behavioral correlates, and integration with publicly available HABI patient datasets. The platform builds on Modulo's triculture system, which previously yielded therapeutic candidates for amyotrophic lateral sclerosis/frontotemporal dementia now in IND-enabling studies. The period of performance ends February 29, 2028. Place of performance is California, USA.
Description
- Abstract
- Despite antiretroviral therapy (art), HIV-associated brain injury (HABI) persists in over half of people with HIV (PWH), manifesting as chronic cognitive impairment. While HIV-1 primarily infects microglia, driving central nervous system (CNS) neuroinflammation, current preclinical models do not recapitulate the chronic, suppressed infection characteristic of the art ERA. Furthermore, they do not capture complex patient genetics and multicellular, glial and neuronal, interactions in a scalable and efficient manner. To address this need for more physiologically relevant models, we propose the development of an AI-guided triculture platform comprising major CNS cell types. This platform will use induced pluripotent stem cell (IPSC)-derived microglia, astrocytes, and neurons, using both morphological profiling and other omics-based profiling to model HABI under art suppression. AI/machine learning (ML)-driven analysis of cellular morphology, combined with multi-omic data integration, will facilitate rapid classification and prediction of microglial functional states and their impact on neuronal health. Leveraging modulo's established triculture system, previously successful in yielding therapeutic candidates for amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) currently in investigational new drug (IND)-enabling studies, we will construct a scalable HABI model under art suppression. Our objectives are to (1) develop and validate an HIV-infected, art-suppressed triculture platform, utilizing AI/ML-driven morphological profiling to classify HABI-specific microglial states; and (2) comprehensively characterize this model through neuroinflammatory profiling, behavioral correlates, and integration with publicly available HABI patient datasets. We hypothesize that our combined computational lab-based triculture system can effectively model HABI pathophysiology under art conditions, enabling both rapid disease state classification and identification of therapeutic targets. Through the integration of experimental and computational approaches, this platform will provide insights into HABI mechanisms and accelerate therapeutic development. We will disseminate this model to the scientific community through publication and collaboration. Connecting in vitro modeling with patient outcomes offers a powerful tool for investigating neuroimmune dysfunction in HIV and related neurological disorders. Successful implementation will yield a platform for modeling neurohiv under art suppression, advancing our understanding of disease mechanisms and facilitating the discovery of novel therapeutic strategies for PWH with cognitive impairment.
Quick answers
Who received award R61MH143793?
R61MH143793 was awarded to Modulo Bio, Inc. by National Institute of Mental Health (National Institutes of Health) on February 25, 2026.
How much is award R61MH143793 worth?
$1,479,470 has been obligated on R61MH143793.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award